TOP TEN perturbations for 40556_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40556_at
Selected probe(set): 201063_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40556_at (201063_at) across 6674 perturbations tested by GENEVESTIGATOR:
OPM-1 / MM1.S
Relative Expression (log2-ratio):-4.9498396Number of Samples:4 / 4
Experimental | OPM-1 |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code: | |
Control | MM1.S |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code: |
expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):3.7455282Number of Samples:3 / 4
Experimental | expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) |
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid. | |
Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-3.2129345Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Relative Expression (log2-ratio):-2.864832Number of Samples:2 / 3
Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
Control | CNS cancer study 1 (PDX; glioblastoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted). |
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Relative Expression (log2-ratio):-2.793562Number of Samples:2 / 2
Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
Control | CNS cancer study 1 (PDX; ependymoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted). |
expO kidney cancer study 1 (renal cell carcinoma, NOS; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):2.7233496Number of Samples:5 / 4
Experimental | expO kidney cancer study 1 (renal cell carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma (NOS). | |
Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
VTX-2337 study 1 / 3M-055 study 1
Relative Expression (log2-ratio):2.6784248Number of Samples:3 / 3
Experimental | VTX-2337 study 1 |
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities. | |
Control | 3M-055 study 1 |
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist. |
T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample
Relative Expression (log2-ratio):2.6125107Number of Samples:2 / 2
Experimental | T-cell activation study 3 |
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs. | |
Control | resting CD4 T-lymphocyte (crude fraction) sample |
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):2.5955925Number of Samples:2 / 2
Experimental | T-cell activation study 1 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
AML study 1 (t(15;17)(q22;q11-12)) / normal bone marrow sample
Relative Expression (log2-ratio):2.5949688Number of Samples:36 / 74
Experimental | AML study 1 (t(15;17)(q22;q11-12)) |
Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RARα and variations). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |